3378 — Hanx Biopharmaceuticals (Wuhan) Co Share Price
0.000.00%
Last trade - 00:00- HK$2.19bn
- HK$2.35bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.71 | ||
| Price to Tang. Book | 11.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.12% | ||
| Return on Equity | -69.68% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hanx Biopharmaceuticals Wuhan Co Ltd is a China-based company mainly engaged in the discovery, development and commercialization of products for precision therapies in cancers and autoimmune diseases. The Company’s core products include HX009, HX301, HX044, and HX008. HX009 is a bifunctional anti-PD-1 antibody SIRP fusion protein, aiming at enhancing PD-1 function and creating a PD-1 molecule. HX301 is a multi-targeted kinase inhibitor with a unique kinase inhibition profile. HX044 is a clinical-stage drug for treatment of various types of malignancies, particularly PD-1-resistant solid tumors. HX008 is a humanized antagonist mAb against human PD-1 by using human IgG4 isotype, which can inhibit the PD-1 signal to restore the capability of the immune cells to kill cancer cells through blocking PD-1 binding to their ligands PD-L1 and PD-L2.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- January 1st, 1970
- Incorporated
- December 19th, 2014
- Public Since
- December 23rd, 2025
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 136,218,830
- Address
- WUHAN
- Web
- http://www.hanxbio.com/
- Phone
- Auditors
- Ernst & Young
Upcoming Events for 3378
Similar to 3378
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the Hanx Biopharmaceuticals (Wuhan) Co share price?
As of Today at 20:02 UTC, shares in Hanx Biopharmaceuticals (Wuhan) Co are trading at HK$16.10. This share price information is delayed by 15 minutes.
How has the Hanx Biopharmaceuticals (Wuhan) Co share price performed this year?
Shares in Hanx Biopharmaceuticals (Wuhan) Co last closed at HK$16.10 and the price had moved by over the past 365 days. In terms of relative price strength the Hanx Biopharmaceuticals (Wuhan) Co share price has matched the FTSE Developed Asia Pacific Index by over the past year.
What are the analyst and broker recommendations for Hanx Biopharmaceuticals (Wuhan) Co?
There is no consensus recommendation for this security.
Find out moreWhat is the Hanx Biopharmaceuticals (Wuhan) Co dividend yield?
Hanx Biopharmaceuticals (Wuhan) Co does not currently pay a dividend.
Does Hanx Biopharmaceuticals (Wuhan) Co pay a dividend?
Hanx Biopharmaceuticals (Wuhan) Co does not currently pay a dividend.
When does Hanx Biopharmaceuticals (Wuhan) Co next pay dividends?
Hanx Biopharmaceuticals (Wuhan) Co does not currently pay a dividend.
How do I buy Hanx Biopharmaceuticals (Wuhan) Co shares?
To buy shares in Hanx Biopharmaceuticals (Wuhan) Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Hanx Biopharmaceuticals (Wuhan) Co?
As of the previous close price of HK$16.10, shares in Hanx Biopharmaceuticals (Wuhan) Co had a market capitalisation of HK$2.19bn.
Where are Hanx Biopharmaceuticals (Wuhan) Co shares listed?
Here are the trading details for Hanx Biopharmaceuticals (Wuhan) Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 3378
What kind of share is Hanx Biopharmaceuticals (Wuhan) Co?
Based on an overall assessment of its quality, value and momentum Hanx Biopharmaceuticals (Wuhan) Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Hanx Biopharmaceuticals (Wuhan) Co share price forecast for 2026?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Hanx Biopharmaceuticals (Wuhan) Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hanx Biopharmaceuticals (Wuhan) Co. Over the past six months, its share price has matched the FTSE Developed Asia Pacific Index by .
As of the last closing price of HK$16.10, shares in Hanx Biopharmaceuticals (Wuhan) Co were trading -4.07% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Hanx Biopharmaceuticals (Wuhan) Co PE Ratio?
The Hanx Biopharmaceuticals (Wuhan) Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$16.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Hanx Biopharmaceuticals (Wuhan) Co?
We do not have data on Hanx Biopharmaceuticals (Wuhan) Co's directors